After developing Herceptin® (TZM)-conjugated NLC containing DTX for HER2-positive breast cancer [45], Varshosaz et al. [46] employed rituximab to target CD20 receptors in lymphoma cells and selected the optimal NLC formulation co-loaded with curcumin and imatinib (a tyrosine kinase inhibitor). Here, ERBB2 is linked to breast cancer.